Form 4: KalVista Pharmaceuticals CEO Benjamin Palleiko Reports Stock Transactions
SEC Form 4 Filing
CEO Benjamin Palleiko reports acquisition and disposal of KalVista Pharmaceuticals stock to cover tax obligations related to vesting of restricted stock units.
Summary
- On March 6, 2025, Benjamin L. Palleiko, CEO of KalVista Pharmaceuticals, acquired 15,625 shares of common stock through the vesting of restricted stock units (RSUs).
- On March 7, 2025, Palleiko sold 6,669 shares of common stock at a price of $11.97 per share.
- The sale was to cover tax withholding obligations associated with the vesting and settlement of the RSUs and was not a discretionary transaction.
- Following these transactions, Palleiko directly owns 287,811 shares of KalVista Pharmaceuticals common stock and 187,501 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment, as it's a factual report of transactions related to compensation and tax obligations.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common for executives receiving stock-based compensation. It provides transparency into the trading activities of company insiders, allowing investors to monitor their actions.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the small number of shares sold by the CEO.
- Employees holding RSUs may be interested in the vesting schedule and tax implications.
Key Dates
| Date | Description |
|---|---|
| June 6, 2024 | Vesting Commencement Date for RSUs, with 1/16th of the total shares vesting quarterly thereafter. |
| March 6, 2025 | Acquisition of 15,625 shares of common stock through RSU vesting. |
| March 7, 2025 | Sale of 6,669 shares of common stock at $11.97 per share to cover tax obligations. |
| March 10, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.